Published in Ann Oncol on May 03, 2006
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol (2014) 6.61
Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol (2014) 2.85
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol (2015) 2.64
Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer (2013) 1.00
Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management. Haematologica (2010) 0.84
The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma. European J Clin Med Oncol (2010) 0.77
Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol (2015) 0.77
Is there a place for routine imaging for patients in complete remission from aggressive lymphoma? Ann Oncol (2006) 0.77
Follow-up care for survivors of lymphoma who have received curative-intent treatment. Curr Oncol (2016) 0.75
Positron emission tomography/computed tomography surveillance in patients with lymphoma: a fox hunt? Haematologica (2012) 0.75
Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse. Case Rep Med (2015) 0.75
Circulating cell-free DNA in hematological malignancies. Haematologica (2016) 0.75
gltB gene and regulation of nitrogen metabolism by glutamine synthetase in Escherichia coli. J Bacteriol (1978) 5.59
Molecular cloning and characterization of the chicken gene homologous to the transforming gene of Rous sarcoma virus. Cell (1981) 3.26
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
Transformation of NIH/3T3 mouse cells by DNA of Rous sarcoma virus. Cell (1979) 2.17
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol (2007) 2.17
W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis. Development (1993) 1.70
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2000) 1.63
Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol (1992) 1.61
Transformation by subgenomic fragments of Rous sarcoma virus DNA. Cell (1980) 1.56
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol (1999) 1.54
The Wsh and Ph mutations affect the c-kit expression profile: c-kit misexpression in embryogenesis impairs melanogenesis in Wsh and Ph mutant mice. Proc Natl Acad Sci U S A (1995) 1.52
The W(sh), W(57), and Ph Kit expression mutations define tissue-specific control elements located between -23 and -154 kb upstream of Kit. Blood (1999) 1.38
Transformation of NIH-3T3 mouse cells by avian retroviral DNAs. Cold Spring Harb Symp Quant Biol (1980) 1.20
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer (2010) 1.19
Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant (2003) 1.13
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant (1999) 1.08
Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol. Blood (2001) 1.08
Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol (2010) 0.98
Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res (1998) 0.96
Temporal specificity in serial feature-positive discrimination learning. J Exp Psychol Anim Behav Process (1997) 0.91
Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification. Ann Oncol (2011) 0.90
Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive and negative subsets and histologic progression. Cytogenet Genome Res (2007) 0.89
Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. Oncogene (2001) 0.89
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol (2003) 0.88
Emerging role of laparoscopy in the diagnosis of lymphoma. J Clin Oncol (1998) 0.87
MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma. Blood (2000) 0.87
Antigen selection in human lymphomagenesis. Cancer Res (1992) 0.85
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol (2012) 0.84
The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant (2009) 0.83
Indications for and efficacy of splenectomy for haematological disorders. Br J Surg (2013) 0.83
Cloning and characterization of a Golgin-related gene from the large-scale polymorphism linked to the PML gene. Genomics (2000) 0.82
A novel L23-related gene 40 kb downstream of the imprinted H19 gene is biallelically expressed in mid-fetal and adult human tissues. Hum Mol Genet (1995) 0.82
Determination of carbon monoxide in blood. Anal Chem (1972) 0.82
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol (2007) 0.81
Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy. Blood (1991) 0.81
Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy. Leuk Lymphoma (2000) 0.81
The PML gene is linked to a megabase-scale insertion/deletion restriction fragment length polymorphism. Genomics (1995) 0.80
Regulation of ribosome synthesis during compensatory renal hypertrophy in mice. Am J Physiol (1987) 0.80
Use of smokeless tobacco by Mexican-American high school students. Psychol Rep (1995) 0.80
Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma. Leuk Lymphoma (2001) 0.80
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Ann Oncol (2009) 0.79
Physical linkage of the lysyl oxidase-like (LOXL1) gene to the PML gene on human chromosome 15q22. Cytogenet Cell Genet (2000) 0.78
Pulsed-field gel electrophoresis analysis of retinoic acid receptor-alpha and promyelocytic leukemia rearrangements. Detection of the t(15;17) translocation in the diagnosis of acute promyelocytic leukemia. Am J Pathol (1993) 0.78
A novel gene STORP (STOmatin-Related Protein) is localized 2 kb upstream of the promyelocytic gene on chromosome 15q22. Eur J Haematol (2000) 0.77
Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. Blood (1990) 0.77
Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas. Clin Cancer Res (1997) 0.76
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Ann Oncol (2004) 0.76
Mucosa-associated lymphoid-tissue lymphoma. N Engl J Med (1993) 0.75
Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits? Curr Oncol Rep (2001) 0.75
Microsatellite instability in breast cancer. Ann Surg Oncol (1997) 0.75